241 related articles for article (PubMed ID: 30030299)
21. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.
Han D; Labaf M; Zhao Y; Owiredu J; Zhang S; Patel K; Venkataramani K; Steinfeld JS; Han W; Li M; Liu M; Wang Z; Besschetnova A; Patalano S; Mulhearn MJ; Macoska JA; Yuan X; Balk SP; Nelson PS; Plymate SR; Gao S; Siegfried KR; Liu R; Stangis MM; Foxa G; Czernik PJ; Williams BO; Zarringhalam K; Li X; Cai C
J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38687617
[TBL] [Abstract][Full Text] [Related]
22. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
[TBL] [Abstract][Full Text] [Related]
23. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening.
Kumar B; Khaleghzadegan S; Mears B; Hatano K; Kudrolli TA; Chowdhury WH; Yeater DB; Ewing CM; Luo J; Isaacs WB; Marchionni L; Lupold SE
Oncotarget; 2016 Nov; 7(45):72593-72607. PubMed ID: 27683042
[TBL] [Abstract][Full Text] [Related]
24. LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.
Regufe da Mota S; Bailey S; Strivens RA; Hayden AL; Douglas LR; Duriez PJ; Borrello MT; Benelkebir H; Ganesan A; Packham G; Crabb SJ
Cancer Cell Int; 2018; 18():71. PubMed ID: 29760584
[TBL] [Abstract][Full Text] [Related]
25. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.
Qiao J; Grabowska MM; Forestier-Roman IS; Mirosevich J; Case TC; Chung DH; Cates JM; Matusik RJ; Manning HC; Jin R
Oncotarget; 2016 Sep; 7(38):61955-61969. PubMed ID: 27542219
[TBL] [Abstract][Full Text] [Related]
26. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Chen S; Cai C; Sowalsky AG; Ye H; Ma F; Yuan X; Simon NI; Gray NS; Balk SP
Cancer Res; 2018 Sep; 78(18):5203-5215. PubMed ID: 30012673
[TBL] [Abstract][Full Text] [Related]
27. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.
Zhang G; Liu X; Li J; Ledet E; Alvarez X; Qi Y; Fu X; Sartor O; Dong Y; Zhang H
Oncotarget; 2015 Sep; 6(27):23358-71. PubMed ID: 26160840
[TBL] [Abstract][Full Text] [Related]
28. Methylselenocysteine preventing castration-resistant progression of prostate cancer.
Liu Y; Liu X; Guo Y; Liang Z; Tian Y; Lu L; Zhao X; Sun Y; Zhao X; Zhang H; Dong Y
Prostate; 2015 Jun; 75(9):1001-8. PubMed ID: 25754033
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
Duan L; Chen YA; Liang Y; Chen Z; Lu J; Fang Y; Cao J; Lu J; Zhao H; Pong RC; Hernandez E; Kapur P; Tran TAT; Smith T; Martinez ED; Ahn JM; Hsieh JT; Luo JH; Liu ZP
Biomed Pharmacother; 2023 Feb; 158():114077. PubMed ID: 36495660
[TBL] [Abstract][Full Text] [Related]
30. Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer.
Neeb A; Figueiredo I; Bogdan D; Cato L; Stober J; Jiménez-Vacas JM; Gourain V; Lee II; Seeger R; Muhle-Goll C; Gurel B; Welti J; Nava Rodrigues D; Rekowski J; Qiu X; Jiang Y; Di Micco P; Mateos B; Bielskutė S; Riisnaes R; Ferreira A; Miranda S; Crespo M; Buroni L; Ning J; Carreira S; Bräse S; Jung N; Gräßle S; Swain A; Salvatella X; Plymate SR; Al-Lazikani B; Long HW; Yuan W; Brown M; Cato ACB; de Bono JS; Sharp A
Mol Cancer Ther; 2024 Jun; 23(6):791-808. PubMed ID: 38412481
[TBL] [Abstract][Full Text] [Related]
31. Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer.
Dyshlovoy SA; Otte K; Alsdorf WH; Hauschild J; Lange T; Venz S; Bauer CK; Bähring R; Amann K; Mandanchi R; Schumacher U; Schröder-Schwarz J; Makarieva TN; Guzii AG; Tabakmakher KM; Fedorov SN; Shubina LK; Kasheverov IE; Ehmke H; Steuber T; Stonik VA; Bokemeyer C; Honecker F; von Amsberg G
Oncotarget; 2016 Oct; 7(43):69703-69717. PubMed ID: 27626485
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.
Shafi AA; Cox MB; Weigel NL
Steroids; 2013 Jun; 78(6):548-54. PubMed ID: 23380368
[TBL] [Abstract][Full Text] [Related]
33. Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer.
Van Etten JL; Nyquist M; Li Y; Yang R; Ho Y; Johnson R; Ondigi O; Voytas DF; Henzler C; Dehm SM
Cancer Res; 2017 Oct; 77(19):5228-5235. PubMed ID: 28928128
[TBL] [Abstract][Full Text] [Related]
34. AR-V7 expression facilitates accelerated G2/M phase transition in castration-resistant prostate cancer.
Saini T; Gupta P; Raut R; Nayak V; Bharathnaveen P; Mishra P; Misra A
Exp Cell Res; 2024 May; 438(1):114026. PubMed ID: 38604522
[TBL] [Abstract][Full Text] [Related]
35. PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
Li Y; Lv L; Ye M; Xie N; Fazli L; Wang Y; Wang W; Yang S; Ni Q; Chen J; Guo X; Zhao Y; Xue G; Sha J; Dong X; Zhang L
Oncogene; 2024 May; 43(21):1631-1643. PubMed ID: 38589675
[TBL] [Abstract][Full Text] [Related]
36. Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism.
Shah S; Carriveau WJ; Li J; Campbell SL; Kopinski PK; Lim HW; Daurio N; Trefely S; Won KJ; Wallace DC; Koumenis C; Mancuso A; Wellen KE
Oncotarget; 2016 Jul; 7(28):43713-43730. PubMed ID: 27248322
[TBL] [Abstract][Full Text] [Related]
37. Tricyclic Diterpenoids Selectively Suppress Androgen Receptor-Positive Prostate Cancer Cells.
Sekhon I; Chen G; Piri K; Shinkawa S; Ashong D; Zhang Q; Wang G; Chen QH
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375297
[TBL] [Abstract][Full Text] [Related]
38. Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.
Pollock JA; Wardell SE; Parent AA; Stagg DB; Ellison SJ; Alley HM; Chao CA; Lawrence SA; Stice JP; Spasojevic I; Baker JG; Kim SH; McDonnell DP; Katzenellenbogen JA; Norris JD
Nat Chem Biol; 2016 Oct; 12(10):795-801. PubMed ID: 27501397
[TBL] [Abstract][Full Text] [Related]
39. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.
Lim M; Otto-Duessel M; He M; Su L; Nguyen D; Chin E; Alliston T; Jones JO
ACS Chem Biol; 2014 Mar; 9(3):692-702. PubMed ID: 24354286
[TBL] [Abstract][Full Text] [Related]
40. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
Antonarakis ES; Chandhasin C; Osbourne E; Luo J; Sadar MD; Perabo F
Oncologist; 2016 Dec; 21(12):1427-1435. PubMed ID: 27628492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
